In AML cells combining the AKT inhibitor ipatasertib (GDC-0068) with venetoclax (Bcl-2 inhibitor) [47], resulted in cell death through BAX, possibly through direct phosphorylation of BAX by AKT increasing association with mitochondria [48]. Here, BCL2 is linked to acute myeloid leukemia.